Page last updated: 2024-12-06

stilbene oxide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Stilbene oxide is a chiral molecule that exists in two enantiomeric forms (cis-stilbene oxide and trans-stilbene oxide). It is a valuable synthetic intermediate for the production of pharmaceuticals and agrochemicals. Its synthesis often involves the epoxidation of stilbene using reagents like m-chloroperbenzoic acid. Stilbene oxide has shown potential as an anti-cancer agent, particularly in the treatment of breast cancer. However, it has also demonstrated toxicity in some studies, highlighting the need for further research to optimize its therapeutic potential. Stilbene oxide is studied extensively due to its importance in various fields including organic synthesis, medicinal chemistry, and environmental science. Its potential application in drug development and its role as a model system for studying enzyme kinetics and reactivity make it a fascinating subject of study.'

stilbene oxide: inducer of epoxide hydratase; RN given refers to cpd without isomeric designation [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID28649
CHEBI ID50006
SCHEMBL ID63809
MeSH IDM0085661

Synonyms (37)

Synonym
LS-14277
nsc133513
bibenzyl,.alpha.'-epoxy-, cis-
nsc-133513
oxirane,3-diphenyl-, cis-
NCIOPEN2_001945
AD-266/40316974
2,3-diphenyloxirane
bibenzyl, .alpha.,.alpha.'-epoxy-
oxirane, 2,3-diphenyl-, cis-
bibenzyl, .alpha.,.alpha.'-epoxy-, cis-
oxirane, 2,3-diphenyl-
bibenzyl,.alpha.'-epoxy-
oxirane,3-diphenyl-
17619-97-5
nsc155516
stilbene oxide
nsc-155516
GHL.PD_MITSCHER_LEG0.611
CHEBI:50006
AKOS000167808
A808136
1,2-diphenylethyleneoxide
A18317
2,3-diphenyl-oxirane
nsc 155516
l47v7xq2xk ,
bibenzyl, alpha,alpha'-epoxy-
unii-l47v7xq2xk
FT-0633541
SCHEMBL63809
2,3-diphenyloxirane #
FT-0772548
oxirane, 2,3-diphenyl- (9ci)
DTXSID20937561
Q27121647
PD193349

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" The same treatment did not produce adverse effects on renal or hepatic functions, but markedly potentiated bromobenzene hepatotoxicity."( Effect of dietary trans-stilbene oxide on hepatic and renal drug-metabolizing enzyme activities and bromobenzene-induced toxicity in male Sprague-Dawley rats.
Hook, JB; Kuo, CH; Maita, K; Rush, GF; Sleight, S, 1984
)
0.57

Pharmacokinetics

ExcerptReferenceRelevance
" However, this experiment further emphasizes the importance of pharmacokinetic considerations when examining interactions in the disposition of xenobiotics."( Enhanced total body clearance of heptachlor from rats by trans-stilbeneoxide.
Rozman, K; Scheufler, E, 1984
)
0.27

Dosage Studied

Trans-stilbene oxide had little effect on the above enzyme activities. These olefins were not detected in the urine or feces of antibiotics-treated rats dosed with cis- or trans-stiltsene oxide.

ExcerptRelevanceReference
" The time course of this increase and of the return to control activity after cessation of treatment, the dose-response of this increase and the structural features of the trans-stilbene oxide molecule which are essential for the increase have all been examined."( The effect of trans-stilbene oxide and other structurally related inducers of drug-metabolizing enzymes on glucuronidation.
DePierre, JW; SeidegÄrd, J, 1982
)
0.78
" Pretreatment (group I) of rats with TSO resulted in elevated fecal excretion of 14C already on the first day after dosing with heptachlor, whereas the effect of the treatment was not apparent in group II and III rats until after 2 days and reached its maximum 3 days after the start of TSO administration."( Enhanced total body clearance of heptachlor from rats by trans-stilbeneoxide.
Rozman, K; Scheufler, E, 1984
)
0.27
" Increasing dosage of trans-stilbene oxide from 400 mg/kg to 1000 mg/kg had little effect on the above enzyme activities."( Variations in induction of drug-metabolizing enzymes by trans-Stilbene oxide in rodent species.
Emerole, GO; Thabrew, MI, 1983
)
0.8
" The time course and dose-response of the increases in glucose 6-phosphate and 6-phosphogluconate dehydrogenase activities have been characterized."( The effect of trans-stilbene oxide and other structurally related inducers of drug-metabolizing enzymes on the pentose phosphate pathway and other enzymes of carbohydrate metabolism.
DePierre, JW; SeidegÄrd, J, 1982
)
0.59
" The time course and dose-response relationship of the induction brought about by trans-stilbene oxide were determined."( Effect of inducers of drug-metabolizing enzymes on glutathione reductase and glutathione peroxidase in rat liver.
Carlberg, I; Depierre, JW; Mannervik, B, 1981
)
0.48
" However, these olefins were not detected in the urine or feces of antibiotics-treated rats dosed with cis- or trans-stilbene oxide."( Reductive metabolism of stilbene oxide and styrene oxide to the olefins in rats.
Kitamura, S; Maeda, C; Mita, M; Shiraishi, Y; Sueki, H; Tatsumi, K, 2000
)
0.82
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
epoxideAny cyclic ether in which the oxygen atom forms part of a 3-membered ring.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (145)

TimeframeStudies, This Drug (%)All Drugs %
pre-199073 (50.34)18.7374
1990's34 (23.45)18.2507
2000's19 (13.10)29.6817
2010's15 (10.34)24.3611
2020's4 (2.76)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 34.19

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index34.19 (24.57)
Research Supply Index5.03 (2.92)
Research Growth Index4.38 (4.65)
Search Engine Demand Index46.22 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (34.19)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (0.66%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other150 (99.34%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]